Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

NCT00372593 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00372593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00372593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2006
Completion date
September 30, 2020
Enrollment
1,070 (actual)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia